zurück

Upadacitinib (new indication: non-radiographic axial spondyloarthritis)

 

Subject:

  • Active Sustance: Upadacitinib
  • Name: Rinvoq®
  • Therapeutic area: Axial spondyloarthritis
  • Pharmaceutical company: AbbVie Deutschland GmbH & Co. KG

 

Time table:

  • Start: 01.09.2022
  • Final decision by G-BA: 16.02.2023

 

Final decision:

  1. Patients who have responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs): No additional benefit proved
  2. Patients who have responded inadequately to previous therapy with biologic antirheumatic drugs (bDMARDs), or who are intolerant to those drugs: No additional benefit proved